Ankylosing Spondylitis Treatment Market Projected to Reach USD 10.39 Billion by 2030, as Oral and Biosimilar Therapies Gain Traction

AI News Q&A (Free Content)

Q1: What are the current treatment options available for Ankylosing Spondylitis and how do they function?

A1: Ankylosing Spondylitis (AS) is primarily managed through a combination of medication, physical therapy, and in severe cases, surgery. Medications such as NSAIDs, TNF inhibitors, IL-17 antagonists, and DMARDs are commonly used to alleviate pain and inflammation. Glucocorticoid injections are utilized for acute flare-ups. These treatments aim to relieve symptoms and halt disease progression by counteracting long-term inflammatory processes. However, there is no known cure for AS.

Q2: How does the global Ankylosing Spondylitis Treatment Market project to grow by 2030?

A2: The Ankylosing Spondylitis Treatment Market is expected to expand significantly, reaching approximately USD 10.39 billion by 2030. This growth is driven by wider recognition of axial spondyloarthritis as a distinct disease, faster MRI-based diagnosis, and expanding reimbursement for advanced biologics and biosimilars. The market is projected to grow at a CAGR of 7.75% during the forecast period from 2025 to 2030.

Q3: What is the role of the gut microbiome in the pathogenesis of Ankylosing Spondylitis?

A3: Recent research has suggested that the gut microbiome plays a significant role in the pathogenesis of Ankylosing Spondylitis. Shared microbial dysbiosis may contribute to the development of AS and other chronic immune-mediated inflammatory diseases like inflammatory bowel disease. Ongoing studies aim to elucidate the complex relationship between microbial characteristics and the disease's pathophysiology.

Q4: What advancements have been made in the automatic scoring of spinal X-rays for Ankylosing Spondylitis?

A4: Advancements in automatic scoring of spinal X-rays for AS have been made with the development of a 2-step auto-grading pipeline called VertXGradeNet. This system predicts modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) for cervical and lumbar vertebral units in X-ray imaging. It shows potential to streamline the reading of spinal radiographs, thereby reducing future clinical trial costs.

Q5: How do genetic factors contribute to the prevalence of Ankylosing Spondylitis?

A5: Ankylosing Spondylitis is influenced by genetic factors, with more than 90% of affected individuals in regions like the UK possessing the HLA-B27 antigen. This genetic predisposition is a significant factor in the development of AS, although environmental factors also play a role. Genetic testing is often a part of the diagnostic process.

Q6: What are the implications of biosimilar therapies in the treatment of Ankylosing Spondylitis?

A6: Biosimilar therapies offer a promising alternative in the treatment of Ankylosing Spondylitis by providing similar efficacy to existing biologic treatments but at a lower cost. The use of biosimilars is expanding, driven by increasing reimbursement and healthcare policies that aim to improve treatment accessibility and affordability.

Q7: Which regions are expected to see the fastest growth in the Ankylosing Spondylitis Treatment Market?

A7: The Asia-Pacific region is expected to experience the fastest growth in the Ankylosing Spondylitis Treatment Market, with a projected CAGR of 9.21% through 2030. This growth is supported by rising disease prevalence, expanding insurance coverage, government biosimilar programs, and a growing network of rheumatology clinics.

References:

• Wikipedia on Ankylosing Spondylitis
• Mordor Intelligence - Ankylosing Spondylitis Treatment Market
• Oral-gut microbiome axis in a Korean cohort with inflammatory bowel disease and ankylosing spondylitis (INTEGRATE)
• Towards Automatic Scoring of Spinal X-ray for Ankylosing Spondylitis
• Industry ARC - Ankylosing Spondylitis Treatment Market
• Grand View Research - Ankylosing Spondylitis Market
• Allied Market Research - Ankylosing Spondylitis Market